REGOLIEVA 40 MG

A useful way to understand Regorafenib is to start with the biology it targets. Inhibits multiple kinases involved in angiogenesis, tumor proliferation and microenvironment signaling. Its activity across vascular and other kinase pathways gives it a broader molecular footprint than a single-target inhibitor, helping explain its use across several tumor types. The database classifies it as Targeted Therapy; Multikinase Inhibitor and associates it with Colorectal; GIST; HCC. Its principal oncology indications are Metastatic colorectal cancer; gastrointestinal stromal tumor after imatinib and sunitinib; hepatocellular carcinoma after sorafenib. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are Regorafenib monotherapy. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. The pharmacology helps explain its individual position among related medicines. This description summarizes the supplied clinical information without giving individualized dosing or treatment instructions. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.